Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

285 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Investigation of Hematuria.
Bolenz C, Schröppel B, Eisenhardt A, Schmitz-Dräger BJ, Grimm MO. Bolenz C, et al. Among authors: grimm mo. Dtsch Arztebl Int. 2018 Nov 30;115(48):801-807. doi: 10.3238/arztebl.2018.0801. Dtsch Arztebl Int. 2018. PMID: 30642428 Free PMC article. Review.
Prediction of 90-day mortality after radical cystectomy for bladder cancer in a prospective European multicenter cohort.
Aziz A, May M, Burger M, Palisaar RJ, Trinh QD, Fritsche HM, Rink M, Chun F, Martini T, Bolenz C, Mayr R, Pycha A, Nuhn P, Stief C, Novotny V, Wirth M, Seitz C, Noldus J, Gilfrich C, Shariat SF, Brookman-May S, Bastian PJ, Denzinger S, Gierth M, Roghmann F; PROMETRICS 2011 research group. Aziz A, et al. Eur Urol. 2014 Jul;66(1):156-63. doi: 10.1016/j.eururo.2013.12.018. Epub 2013 Dec 27. Eur Urol. 2014. PMID: 24388438
Optimizing outcome reporting after radical cystectomy for organ-confined urothelial carcinoma of the bladder using oncological trifecta and pentafecta.
Aziz A, Gierth M, Rink M, Schmid M, Chun FK, Dahlem R, Roghmann F, Palisaar RJ, Noldus J, Ellinger J, Müller SC, Pycha A, Martini T, Bolenz C, Moritz R, Herrmann E, Keck B, Wullich B, Mayr R, Fritsche HM, Burger M, Bastian PJ, Seitz C, Brookman-May S, Xylinas E, Shariat SF, Fisch M, May M; PROMETRICS 2011 Research Group. Aziz A, et al. World J Urol. 2015 Dec;33(12):1945-50. doi: 10.1007/s00345-015-1572-x. Epub 2015 May 7. World J Urol. 2015. PMID: 25947885
Prediction of Locally Advanced Urothelial Carcinoma of the Bladder Using Clinical Parameters before Radical Cystectomy--A Prospective Multicenter Study.
Martini T, Aziz A, Roghmann F, Rink M, Chun FK, Fisch M, Trojan L, Hakenberg OW, Zastrow S, Wirth MP, Moersdorf J, Brookman-May S, Stief CG, Haferkamp A, Wagenlehner F, Hohenfellner M, Herrmann E, Lusuardi L, Grimm MO, Müller SC, Roigas J, Bastian PJ, Gierth M, Burger M, Pycha A, Seitz C, May M, Bolenz C. Martini T, et al. Among authors: grimm mo. Urol Int. 2016;96(1):57-64. doi: 10.1159/000433606. Epub 2015 Jul 1. Urol Int. 2016. PMID: 26139354
The Use of Neoadjuvant Chemotherapy in Patients With Urothelial Carcinoma of the Bladder: Current Practice Among Clinicians.
Martini T, Gilfrich C, Mayr R, Burger M, Pycha A, Aziz A, Gierth M, Stief CG, Müller SC, Wagenlehner F, Roigas J, Hakenberg OW, Roghmann F, Nuhn P, Wirth M, Novotny V, Hadaschik B, Grimm MO, Schramek P, Haferkamp A, Colleselli D, Kloss B, Herrmann E, Fisch M, May M, Bolenz C. Martini T, et al. Among authors: grimm mo. Clin Genitourin Cancer. 2017 Jun;15(3):356-362. doi: 10.1016/j.clgc.2016.09.003. Epub 2016 Sep 19. Clin Genitourin Cancer. 2017. PMID: 27765613
Effect of Hospital and Surgeon Case Volume on Perioperative Quality of Care and Short-term Outcomes After Radical Cystectomy for Muscle-invasive Bladder Cancer: Results From a European Tertiary Care Center Cohort.
Vetterlein MW, Meyer CP, Leyh-Bannurah SR, Mayr R, Gierth M, Fritsche HM, Burger M, Keck B, Wullich B, Martini T, Bolenz C, Pycha A, Hanske J, Roghmann F, Noldus J, Bastian PJ, Gilfrich C, May M, Rink M, Chun FK, Dahlem R, Fisch M, Aziz A; PROMETRICS 2011 study group. Vetterlein MW, et al. Clin Genitourin Cancer. 2017 Oct;15(5):e809-e817. doi: 10.1016/j.clgc.2017.04.021. Epub 2017 Apr 26. Clin Genitourin Cancer. 2017. PMID: 28550955
SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11).
Retz M, Bedke J, Bögemann M, Grimm MO, Zimmermann U, Müller L, Leiber C, Teber D, Wirth M, Bolenz C, van Alphen R, De Santis M, Beeker A, Lehmann J, Indorf M, Frank M, Bokemeyer C, Gschwend JE. Retz M, et al. Among authors: grimm mo. Eur J Cancer. 2019 Jan;107:37-45. doi: 10.1016/j.ejca.2018.11.001. Epub 2018 Dec 7. Eur J Cancer. 2019. PMID: 30529901 Clinical Trial.
In Reply.
Bolenz C, Schröppel B, Eisenhardt A, Schmitz-Dräger BJ, Grimm MO. Bolenz C, et al. Among authors: grimm mo. Dtsch Arztebl Int. 2019 Mar 8;116(11):192-193. doi: 10.3238/arztebl.2019.0192b. Dtsch Arztebl Int. 2019. PMID: 31014454 Free PMC article. No abstract available.
Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS".
Grimm MO, van der Heijden AG, Colombel M, Muilwijk T, Martínez-Piñeiro L, Babjuk MM, Türkeri LN, Palou J, Patel A, Bjartell AS, Caris C, Schipper RG, Witjes WPJ; EAU Research Foundation NIMBUS Study Group. Grimm MO, et al. Eur Urol. 2020 Nov;78(5):690-698. doi: 10.1016/j.eururo.2020.04.066. Epub 2020 May 20. Eur Urol. 2020. PMID: 32446864 Clinical Trial.
285 results